Adding pembrolizumab to chemoradiotherapy improves survival in newly diagnosed locally advanced cervical cancer. Despite that, the addition of the immunotherapy was not found to be cost-effective at a ...
Inhibrx Biosciences (NASDAQ:INBX) reported interim randomized Phase 2 data for INBRX-106 in combination with Merck's KEYTRUDA in first-line PD-L1-positive head and neck squamous cell carcinoma, with ...
The Food and Drug Administration (FDA) has granted Priority Review to enfortumab vedotin-ejfv (Padcev ™) in combination with pembrolizumab (Keytruda ®) or pembrolizumab and berahyaluronidase alfa-pmph ...
What Is Keytruda/Padcev Combination Therapy, and Why Does It Matter? The FDA has approved a new combination therapy that uses two different types of anticancer medicines for treating adults with ...
The FDA has approved enfortumab vedotin (Padcev, Astellas Pharma) in combination with pembrolizumab (Keytruda, Merck) or subcutaneous pembrolizumab (Keytruda Qlex, Merck) for the neoadjuvant and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results